论文信息 - Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. - 字舞流文

Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.

S. Cherry | L. Nardo | J. Riess | D. Gandara | P. Paik | R. Badawi | D. Shackelford | P. Frankel | M. Dunphy | P. Lara | W. Gonsalves | C. Kunos | J. Reid | E. Newman | Ian Lanza | I. Lanza